MeSH D017681 - hypereosinophilic syndrome
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Imatinib | Imatinib | 2016-08-04 | |||
| Imatinib | Imatinib Teva | 2013-01-07 | ||||
| Imatinib | Imatinib Teva B.V | 2017-11-15 | ||||
| Mylan | Imatinib | Imatinib | 2017-06-21 | |||
| Novartis | Imatinib | Gleevec | 2001-05-10 | $887 M | Q2/20-Q2/23 | |
| Imatinib | Glivec | 2001-11-07 | ||||
| Dr Reddys Laboratories | Imatinib | Imatinib | 2018-08-13 | |||
| Zydus Therapeutics | Imatinib | Imatinib | 2020-04-08 | |||
| Sun Pharmaceutical Industries | Imatinib | Imatinib | 2015-12-03 | |||
| Apotex | Imatinib | Imatinib | 2016-08-05 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
100%2/2
Phase 2
13%1/8
Phase 3
64%9/14
Approved: 7Overall Success rate: 8%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use